Specifically, it is suggested that exogenous erythropoietin generated by ESAs can largely increase C-terminal fibroblast growth factor 23 (FGF23) levels [23], which is significantly associated with left ventricular hypertrophy and an increased risk of mortality. Here, FGF23 is linked to left ventricular hypertrophy.